The lowest price for Centessa Pharmaceuticals stock of the stock of Centessa Pharmaceuticals is $18.77 by Investing.com.
Centessa Pharmaceuticals ADR (CNTA) stock rose to a 52-week high, reaching a price level of $18.77. This milestone marks a significant turnaround for the company, which has seen a staggering 168.84% turnover over the past year. According to InvestingPro data, analysts maintain a strong buy consensus with price targets ranging from $24 to $35, suggesting a potential upside. Investors have shown more confidence in Centessa’s strategic plans and pipeline development, driving the stock higher. With a strong current ratio of 21.5 and more than debt on its balance sheet, the company maintains a strong financial position. The company’s recent performance has surpassed many of its peers in the biotechnology sector, as it continues to focus on improving its pharmaceutical research and development. InvestingPro subscribers can access 12 additional investment tips and a complete Pro Research Report for in-depth insights into CNTA’s strengths.
In other recent news, Centessa Pharmaceuticals has seen positive growth in its product line. Leerink Partners raised Centessa’s stock price to $24, maintaining an Outperform rating due to a promising update for the Phase 1 ORX750 program. The program targets orexin receptor 2 agonists and Leerink Partners raised its forecast for Centessa’s 2032 net sales by 4% and earnings per share by 18%. Guggenheim also raised its price target for Centessa to $28, maintaining a buy rating based on strategic improvements, particularly updates to the ORX750. BMO Capital Markets maintained its Outperform rating and $35.00 price target on Centessa, based on new ORX142 data, which supports the company’s leading position in the orexin agonist market. Currently, Morgan Stanley (NYSE: ) upgraded Centessa to Overweight, raising its price target to $26, following promising Phase 1 interim results from the company’s ORX750 study. These latest developments highlight Centessa’s ongoing efforts in the pharmaceutical industry.
This article was created with the support of AI and reviewed by an editor. For more information see our T&C.
